Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Articolo
Data di Pubblicazione:
2017
Citazione:
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer / Bianchini, G; Kiermaier, A; Bianchi, Gv; Im, Yh; Pienkowski, T; Liu, Mc; Tseng, Lm; Dowsett, M; Zabaglo, L; Kirk, S; Szado, T; Eng-Wong, J; Amler, Lc; Valagussa, P; Gianni, L.. - In: BREAST CANCER RESEARCH. - ISSN 1465-5411. - (2017).
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Bianchini, G; Kiermaier, A; Bianchi, Gv; Im, Yh; Pienkowski, T; Liu, Mc; Tseng, Lm; Dowsett, M; Zabaglo, L; Kirk, S; Szado, T; Eng-Wong, J; Amler, Lc; Valagussa, P; Gianni, L.
Link alla scheda completa:
Pubblicato in: